Thavalingam, Annoj
Cheng, Zhi
Garcia, Bianca
Huang, Xue
Shah, Megha
Sun, Wei
Wang, Min
Harrington, Lucas
Hwang, Sungwon
Hidalgo-Reyes, Yurima
Sontheimer, Erik J. http://orcid.org/0000-0002-0881-0310
Doudna, Jennifer http://orcid.org/0000-0001-9161-999X
Davidson, Alan R. http://orcid.org/0000-0002-0744-9199
Moraes, Trevor F.
Wang, Yanli
Maxwell, Karen L. http://orcid.org/0000-0002-0211-5480
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (PJT-152918, FDN-15427)
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (RGPIN-2018-06546)
Foundation for the National Institutes of Health (GM125797)
Ministry of Science and Technology of the People's Republic of China (2017YFA0504203)
National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (31725008)
Article History
Received: 16 April 2019
Accepted: 15 May 2019
First Online: 26 June 2019
Competing interests
: J.D. is a co-founder of Caribou Biosciences, Editas Medicine, Intellia Therapeutics, Scribe Therapeutics and Mammoth Biosciences, and a Director of Johnson & Johnson. J.D. is a scientific advisor to Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Synthego, Metagenomi, Mammoth Biosciences, and Inari. J.D. has research projects sponsored by Biogen and Pfizer. L.H. is a co-founder of Mammoth Biosciences. E.J.S. is a co-founder of Intellia Therapeutics. The other authors declare no competing interests.